2 - 3 november 2017 cambridge - embl-ebi · biodata eu 2017 day 1 08:55 chair’s opening remarks...

2 - 3 November 2017

Cambridge

Latest conference

schedule

To register to attend and the latest offer click here »To speak, contact Chris Shanks »To sponsor or exhibit contact Alistair Wilmot »

https://secure.terrapinn.com/V5/step1.aspx?E=9208

mailto:[email protected]


Contents

Speakers Data Storage & Management

Data Computing & Processing/BioData of the Future Transforming Big Data into Smart Data

Data Discovery & Generation/Innovation Showcase/Population & Public Health

BioData World Congress 2017 of 37

Accurate as of 22 August 2017. Always refer to our website for the latest updates www.terrapinn.com/biodata

http://www.terrapinn.com/conference/biodata

Speakers

Ed Addison, Chief Executive Officer, Cloud PharmaceuticalsBissan Al Lazikani, Head of Data Science, Institute of Cancer ResearchSharmini Alagaratnam, Principal Investigator, BigMed (DNV GL Research)Rolf Apweiler, EMBL-EBI Director, EMBL- EBIPedro Ballester, group leader, INSERMNatalie Banner, Policy Adviser, The Wellcome TrustJeff Barrett, Vice President of Translational Informatics, Sanofi IncStuart Bayliss, Business Support Manager, Central Manchester University Hospitals N.H.S. Foundation TrustEerke Boiten, Professor of Cyber Security, De Montfort UniversityKai-Gerhard Bosch, Cloud/Emerging Technology Architect, Merck KGaAFrancesca Buffa, Associate Professor, University of OxfordSir John Burn, Non-executive director, Professor of Clinical Genetics, NHS England & Newcastle UniversityMauricio Carneiro, Head of Scientific Software, Verily (Google Life Sciences)Mark Caulfield, Chief Scientist, Genomics EnglandMaria Chatzou, Research Bioinformatics Engineer & President, Innovation Forum Barcelona, Center For GenomicRegulation C.R.G.Tom Chittenden, Vice President, Statistical Sciences and Founding Director, Advanced Artificial Intelligence ResearchLaboratory, WuXi NextCODEJo Churchill, MP, Member of ParlimentAntonio Criminisi, Principal Researcher, Microsoft ResearchEmanuele De Rinaldis, Honorary Senior Lecturer & Head of Translational Bioinformatics, NIHR Biomedical ResearchCentre, Kings College of LondonSean Ennis, Research & Analytics, Founder, Genomics Medicine IrelandLorna Ewart, Head of IMED MPS Centre of Excellence, AstraZenecaDavid Fenstermacher, Vice President - Research & Development, MedImmune IncEnrico Ferrero, Scientific Leader (Computational Biology and Stats), GSKPeter Frommolt, Head of Bioinformatics Facility, University of CologneAndy Grant, Vice President, Head of Big Data, H.P.C. and Cybersecurity For U.K. and Ireland, AtosTim Guilliams, CEO, HealxJennifer Hall, Chief, Institute for Precision Cardiovascular Medicine, American Heart AssociationShahid Hanif, Head of Health Data and Outcomes, A.B.P.I.Per Hansen, Regional Manager Sales Engineering, Aspera, an IBM Co.Patrick Harnett, Consultant physician and nephrologist, Southend University Hospital NHS Foundation TrustAthula Herath, Global Head of Real world Evidence Disease Epidemiology, NovartisZdenko Herceg, Head, Section of Mechanisms of Carcinogenesis, International Agency for Research on Cancer(IARC/WHO)Aasta Hetland, Senior Advisor, Norwegian Directorate for e-healthMark Ibberson, Bioinformatics Scientist, Vital-IT, Swiss Institute of BioinformaticsSumit Jamuar, Chairman, Global Gene CorpHans-Josef Jeanrond, , SinequaDavid Jenkinson, Chief Scientific Officer, The Brain Tumour CharityAndreas Jerrentrup, Deputy Director, Undiagnosed and Rare Diseases Centre, University Hospital of Giessen andMarburgDipak Kalra, President, The European Institute for Innovation through Health DataMisha Kapushesky, CEO, Genestack




Johannes Karten, Chief Technology Officer, GENALICEPearse Keane, NIHR Clinician Scientist and Honorary Consultant Ophthalmologist, Moorfields Eye Hospital NHSFoundation TrustPatrick Keohane, Chief Medical Officer, Benevolent A.I.Alexander Krupp, Head of Computational Life Science IT Pharmaceuticals, BayerJan Kuentzer, Head of Data Science Application Services, Roche Pharmaceutical Research and EarlyDevelopment, Roche Innovation Center MunichOwen Lancaster, Bioinformatics and Epidemiology Analyst, Public Health EnglandJean Louis Mandel, Professor of Human Genetics, Collège de FranceRuth March, Vice President and Head of Personalized Healthcare and Biomarkers, AstraZenecaKeith McNeil, Chief Clinical Information Officer, Health & Social Care, NHS EnglandClaus Nielsen, Public Affairs, Personal Connected Health AllianceRuth Norris, Programme Manager, The University Of ManchesterNicola Orlandi, Head Data Privacy Pharma, NovartisRadouane Oudrhiri, Chief Data Scientist, Eagle Genomics LtdDavid Pearce, President, Sanford ResearchAdam Platt, Global Head of Genomics Portfolio, Head of the RIA Companion Diagnostic Unit (RIA CDU) inPersonalised Healthcare and Biomarkers, AstraZenecaPhil Quinlan, Director, UKCRC Tissue Directory and Coordination CentreSobia Raza, Senior Policy Analyst, Data Science, PHG FoundationAndrew Roddam, Vice President & Global Head Epidemiology, GSKAmr Saeb, Head, Genetics and Biotechnology Department, Strategic Center for Diabetes Research, King SaudUniversity, Kingdom of Saudi ArabiaVishal Sahni, Director, Pipeline Strategy and R&D Partnerships, Rare Diseases Unit, GSKPhilippe Sanseau, Head Computational Biology and Stats, GSKMatthieu-P. Schapranow, Program Manager E-Health & Life Sciences, Hasso Plattner InstituteSerena Scollen, Head of Human Genomics and Translational Data, ELIXIRRichard Scott, Clinical Lead for 100,000 Genomes Project Rare Disease, Genomics EnglandDavid Smith, Professor of Laboratory Medicine And Pathology, Mayo ClinicJayne Spink, Chief Executive Officer, Genetic Alliance U.K.Timothy Stitt, Head of Scientific Computing, Earlham InstituteKaren Temple, Professor of Medical Genetics within Medicine, NHS EnglandDimitar Tonev, Director of Medical Affairs, Intercept Pharmaceuticals IncMary Tully, Director of Public Engagement, Connected Health CitiesTjeerd Van Staa, Professor in Health e-Research, The University of ManchesterJames Weatherall, Executive Director & Head, Advanced Analytics Centre, AstraZenecaTony Whetton, Director, Stoller Biomarker Discovery Centre,Manchester Precision Medicine InstituteJulia Wilson, Associate Director, Wellcome Trust Sanger InstituteJohn Wise, Executive Director, Pistoia AllianceMathew Woodwark, Director of Research Bioinformatics, Medimmune LtdIoannis Xenarios, Director, Swiss-Prot/Vital-IT Group, Swiss Institute of Bioinformatics








Data Storage & Management

Biodata pre-conference day 2017

12:00 Registration opens & welcome lunch

13:30 Welcome remarks

13:35 Chair's remarks

Radouane Oudrhiri, Chief Data Scientist, Eagle Genomics Ltd

13:40 Session 1: User case studies• Hear from those involved in the analysis of integrated data as well as different ways organisations are

tackling data management• What are some of the challenges encountered by these groups that are impeding generation of results?• Current bottlenecks of the bio-data workflow

14:40 Networking afternoon break

15:10 Session 2: Technological Solutions• Review in small discussion groups technological solutions that support the methods, processes and

approaches discussed in Session 1• Best practices and strategies for data management & data governance• What technologies support data integration & analytics?• Review semantic integration, metadata and standardisation

16:10 End of Pre-Conference Workshop




BioData EU 2017 Day 1

08:55 Chair’s opening remarks

Julia Wilson, Associate Director, Wellcome Trust Sanger Institute

KEYNOTE: IMPLEMENTING BIG DATA ACROSS LIFE SCIENCES R&DAND DRUG DISCOVERY

One-on-one interviews with some of biodata’s principal thought-leaders, discussingwhat they are doing to enable the implementation of big data across in their R&Dpipelines and within healthcare practices

09:00 Update on AstraZeneca’s Integrated Genomics Initiative

Ruth March, Vice President and Head of Personalized Healthcare and Biomarkers,AstraZeneca

09:20 Experimental and computational platforms at Verily Life Sciences

Mauricio Carneiro, Head of Scientific Software, Verily (Google Life Sciences)

10:00 Speed Networking

10:20 NETWORKING REFRESHMENT BREAK

11:00 Building more predictive and interpretable in silico models of in vivo drugresponse via model complexity control• Hear an overview of how the high dimensionality of pharmacogenomics data hampers the discovery of

complex molecular markers• Gain an understanding of ways to improve the performance of machine learning algorithms on high-

dimensional data in the context of precision oncology• Examine how to assess which molecular profiles are most predictive of PDX response depending on

treatment and cancer type

Pedro Ballester, group leader, INSERM

11:20 Reserved for a platinum partner

Andy Grant, Vice President, Head of Big Data, H.P.C. and Cybersecurity For U.K. andIreland, Atos




11:40 Bio IT and BioData Roundtables: Click here to view tablesParticipants take part in two 40 minute roundtables, discussing together with the expert moderator keychallenges and opportunities within bio IT and biodata. Topics include:

12:20 Roundtables

Maria Chatzou, Research Bioinformatics Engineer & President, Innovation ForumBarcelona, Center For Genomic Regulation C.R.G.

Ruth Norris, Programme Manager, The University Of Manchester

Adam Platt, Global Head of Genomics Portfolio, Head of the RIA Companion DiagnosticUnit (RIA CDU) in Personalised Healthcare and Biomarkers, AstraZeneca

David Pearce, President, Sanford Research

Eerke Boiten, Professor of Cyber Security, De Montfort University

Tim Guilliams, CEO, Healx

13:00 NETWORKING LUNCH BREAK

DATA STORAGE & MANAGEMENT

DATA INTEGRATION & INTEROPERABILITY


Serena Scollen, Head of Human Genomics and Translational Data, ELIXIR

14:20 Integrating proteomics in precision medicine• Gain an understanding of the role proteomics is playing in precision medicine, and their benefits

beyond genomics• Best practices in integrating multi-omics data• Explore the latest developments within mass spectrometry methods

Tony Whetton, Director, Stoller Biomarker Discovery Centre,Manchester PrecisionMedicine Institute




14:40 Infrastructure development for Europe’s human genomics data• Gain an understanding of human data discovery through ELIXIR Beacon project• Challenges in managing human genomics data in rare diseases and common complex diseases -

working across different countries and multiple institutions• How can this infrastructure enable new insights leading to improved healthcare outcomes?

Serena Scollen, Head of Human Genomics and Translational Data, ELIXIR

15:00 Genomic data sharing and integration for clinical applications• Insights into drivers and barriers to genomic data sharing and integration in the NHS• What is the clinical necessity?• What are some of the ethical and legal dimensions?

Sobia Raza, Senior Policy Analyst, Data Science, PHG Foundation

15:20 Data Curation• Gain an understanding of ways to curate and weave complex data types to make them useful for

analysis?• What have been some of the major challenges to overcome when working with biological, clinical and

RWE data sets?• What role does automation play in data curation?




OPEN-SOURCE DATA MODELS


Philippe Sanseau, Head Computational Biology and Stats, GSK

16:25 Case Study: Open Targets• Hear about the new data being generated as part of the Open Targets public-private initiative• Update on the bioinformatics platform• What is the progress being made in experimental data and how are they integrating that data into the

platform?

Philippe Sanseau, Head Computational Biology and Stats, GSK




16:45 Data-sharing across borders: A Nordic case study• What are some of the ethical, legal and technical issues encountered in sharing data across Nordic

borders, and what are possible solutions?• Lessons learnt from both the Nordic Network and the BigMed Project that can be applied in other

geographies• Exploring the value of the third party role in data sharing

Sharmini Alagaratnam, Principal Investigator, BigMed (DNV GL Research)

17:25 Realising the potential of big data through multi-national open-source datasharing• Update on the work EMBL-EBI are undertaking• Why is it important to have multi-national open-source data sharing platforms within biodata?• What are some of the implementation challenges around national rules and regulations, governance

and project funding?

Rolf Apweiler, EMBL-EBI Director, EMBL- EBI

17:45 END OF DAY 1 – NETWORKING DRINKS RECEPTION


08:55 Chairman’s remarks and recap of Day 1

Jo Churchill, MP, Member of Parliment

KEYNOTE: IMPLEMENTING BIG DATA ACROSS HEALTHCARESYSTEMS

09:00 Keynote Interview – Healthcare & Data: Implementing the NHS patient “data lake”

Keith McNeil, Chief Clinical Information Officer, Health & Social Care, NHS England




09:40 Panel: Data Security & Protection: Where is the patient in all of this?• How do you engage people? What innovative approaches can be used to engage the public? Social

media? Lessons learnt from social services and education outreach programmes.• How do diverse communities feel about sharing their data?• What is realistic in terms of patients’ knowledge of how their medical data is being used in research?• Discussions around ‘consent’ or ‘opt-out’

Natalie Banner, Policy Adviser, The Wellcome Trust

Jayne Spink, Chief Executive Officer, Genetic Alliance U.K.

Mary Tully, Director of Public Engagement, Connected Health Cities

John Burn, Non-executive director, Professor of Clinical Genetics, NHS England &Newcastle University



DATA SECURITY & PROTECTION


Aasta Hetland, Senior Advisor, Norwegian Directorate for e-health

11:05 Governance requirements for electronic health records and reuse for research• Ethical, privacy protection and governance requirements for electronic health record architectures and

systems• What challenges to this privacy protection does research use pose?• How can clinical research make use of interoperable electronic health records in a trustworthy way?

Dipak Kalra, President, The European Institute for Innovation through Health Data

11:25 Data privacy requirements in pharma• Review challenges faced by pharma companies in data privacy• How do you continue to push scientific development and innovation whilst maintaining adequate data

protection measures?• How does data privacy sit with the pharma business strategy as a whole?

Nicola Orlandi, Head Data Privacy Pharma, Novartis






SUCCESSFUL STRATEGIES FOR R&D DATA MANAGEMENT

13:45 Integration of RWE data in the evaluation of clinical probability of success viaclinical trial simulation• Best practices in modelling to incorporate different data sets• Hear a case study of this application within diabetes• Examine how to create an Integrated Data

Jeff Barrett, Vice President of Translational Informatics, Sanofi Inc

14:05 “How to eat the elephant”: A review of information architecture• How do you make information architecture a priority in corporate environments and deliver immediate

impact?• Insights into a structured approach to overcome the core challenges of large enterprises to build key

data assets• Best practices in applying this to a pharmaceutical R&D business

Alexander Krupp, Head of Computational Life Science IT Pharmaceuticals, Bayer

14:25 Addressing the pain points of bioinformatics R&D in the post-genomic era• Lessons learnt from the pharmaceutical industry• Focus on data and metadata management• Gain an understanding of what’s next for bioinformatics R&D

Misha Kapushesky, CEO, Genestack

14:45 How to manage data in a more structured way• Update into Roche’s data management and workflow management strategy• What have been some of the challenges rolling it out?• How has been accepted by the scientists using the platform?

Jan Kuentzer, Head of Data Science Application Services, Roche PharmaceuticalResearch and Early Development, Roche Innovation Center Munich




CLOSING KEYNOTE: HORIZON SCOPING IN BIODATA


Sumit Jamuar, Chairman, Global Gene Corp

15:10 Panel: The Future of Big Data within Life Sciences• Where are we going with biodata? What is the sense of direction?• What will be the dynamic between biodata and clinical data?• What role will we see alternative sources of data (such as behavioural or environmental data) and new

technologies (such as nanotechnology and wearable) play in their interaction with biodata?• What is the role of AI and machine learning in all of this?• Forward looking perspectives on population-based health studies within biodata. What will the

interface be between real world data/ real world evidence and genomics? Will this help to better informprecision medicine moving forward?

James Weatherall, Executive Director & Head, Advanced Analytics Centre,AstraZeneca

Mark Caulfield, Chief Scientist, Genomics England

John Wise, Executive Director, Pistoia Alliance

15:50 END OF DAY 2 – SEE YOU NEXT YEAR!

PricingThe earlier you book, the more you save…

Before 1 Sep 2017 Before 22 Sep 2017 After 22 Sep 2017

£1,745Save £200

£1,845Save £100

£1,945

Pricing illustrative, please refer to www.terrapinn.com/biodata for current discounts



http://www.terrapinn.com/biodata


Data Computing & Processing/BioData of the Future
















DATA COMPUTING & PROCESSING

UP IN THE CLOUD


Matthieu-P. Schapranow, Program Manager E-Health & Life Sciences, Hasso PlattnerInstitute

14:20 Case Study: Federated In-Memory Database System (FIMDB)• Overview of this platform that boasts the benefits of a public cloud but with private processing

capabilities• Explore the technical foundations of this platform that combines integrated data processing and real-

time data analysis• In what way was there unmet need for such a managed service within academia internationally?

Matthieu-P. Schapranow, Program Manager E-Health & Life Sciences, Hasso PlattnerInstitute

14:40 Lessons learnt from implementing a cloud initiative in pharma• What have been some of the major bottlenecks encountered when moving into the cloud?• Best practices in engaging the research side with the IT side of a pharma business to ensure a

successful transition into the cloud• How do you best consider the business strategy in line with the IT agenda in order to enable and

elevate the pharma business to its greatest potential?

Kai-Gerhard Bosch, Cloud/Emerging Technology Architect, Merck KGaA

15:00 Using the cloud in drug discovery and design• Examine how the cloud is being used to computationally design new drugs• How does this method differ from more traditional drug discovery methods and what are the benefits?• What does the future look like for the combination of AI and cloud computing in the drug discovery

space?

Ed Addison, Chief Executive Officer, Cloud Pharmaceuticals




15:20 Faster Results to Discovery: Adding High-Speed Data Transfer to your CloudApplications• Moving big data to the cloud for collaborative research and pharma applications is nearly impossible

over the internet and shipping hard drives is a risky alternative• Learn how IBM Aspera high-speed transfer software makes it possible securely move data of any size to

the cloud at speeds 100s of times faster than other solutions• Explore best practices from organizations like BGI and Bluebee High Performance Genomics that use

Aspera to accelerate critical cloud-based research and bioinformatics

Per Hansen, Regional Manager Sales Engineering, Aspera, an IBM Co.


DATA COMPUTING & PROCESSING

NGS & NGS INFORMATICS


Sean Ennis, Research & Analytics, Founder, Genomics Medicine Ireland

16:25 Highly scalable NGS data processing between research and clinic• Gain an understanding of how the QuickNGS and CancerSysDB platforms achieve highest throughput

in NGS applications, ranging from basic research to clinical investigation• Hear how this highly scalable approach can crunch large-scale study population data and facilitates

timely analyses of patients' personal genomes• Review challenges including the appropriate deal with national rules for personal data protection,

uninterrupted availability of HPC resources, and maintenance of highly complex analysis codes

Peter Frommolt, Head of Bioinformatics Facility, University of Cologne

16:45 Adoption of NGS in the Mayo Clinic• Insights from a leading clinic as to where NGS is going within healthcare• Review of MP-Seq as a powerful clinical tool• With all the tools Mayo Clinic has, why are they not doing genomes?

David Smith, Professor of Laboratory Medicine And Pathology, Mayo Clinic




17:05 Benefits of whole genome cohort migration to GRCh38• What are the key considerations around performance, storage and quality?• Review best practices in working at scale with large cohorts of whole genome data• What yield can you expect when using GRCh38?

Johannes Karten, Chief Technology Officer, GENALICE

17:25 Case Study: The Qatar Genome Project• Gain an understanding of what is involved in the Qatar Genome Project, and what this means to

genomic studies around the globe• What are the requirements from the chosen data infrastructure?• What implications does this data have both on clinical care and also population health?

Ena Wang, Acting CRO; Research Chief, Translational Medicine, Sidra Medical andResearch Center


















BIODATA OF THE FUTURE

INNOVATIONS IN BIODATA

11:05 Setting the computational standard for scalable genomics and personalisedmedicine analysis• Gain insight into the work being done to create a standard computational method for HPC at a time

when genomics data is growing• What hurdles were met during development?• What opportunities does this standard present to the biodata sector?

Maria Chatzou, Research Bioinformatics Engineer & President, Innovation ForumBarcelona, Center For Genomic Regulation C.R.G.

11:25 How artificial intelligence is innovating drug discovery and development• Gain an understanding of how medical research is seeing rapid transformation driven by an explosion

in data and advances in AI• How is BenevolentAI’s approach, of identifying and developing novel products and novel uses of

existing products, taking advantage of existing data sets, and the need to access and re-evaluatepharmaceutical databases?

• What are the main benefits of this AI-based approach to a drug discovery pipeline: time, attrition,financial, and for patients?

Patrick Keohane, Chief Medical Officer, Benevolent A.I.

11:45 Prediction of novel therapeutic targets using an innovative data approach• Gain a better understanding of the challenges around target identification and validation• Review a semi-supervised classification approach to explore whether gene – disease association data is

sufficient to predict therapeutic targets• Investigate how a neural network is able to predict therapeutic targets with over 70% accuracy

demonstrating that disease association is predictive of the ability of a gene or a protein to work as adrug target

Enrico Ferrero, Scientific Leader (Computational Biology and Stats), GSK




12:05 Integrative Informatics: How to bring semantic and tabular data together to driveinsight

Mathew Woodwark, Director of Research Bioinformatics, Medimmune Ltd


BIODATA OF THE FUTURE

APPLICATIONS OF AI & MACHINE LEARNING WITH BIODATA


Patrick Keohane, Chief Medical Officer, Benevolent A.I.

13:45 AI methodologies and optimisation within childhood cancer• Insights into big data analytics on the causation of a rare childhood cancer• How is this enabling drug discovery for this particular patient cohort?• Investigate methods used to identify drug responses from each patient within that same cohort

Bissan Al Lazikani, Head of Data Science, Institute of Cancer Research

14:05 Artificial intelligence & machine learning applications in clinical development:Present & future• Gain insights into machine learning as applied to the intelligent mining of clinical trials data and

examine predictive analytics to refine the operational execution of drug development• What are some of the challenges & opportunities presented by the burgeoning role of technology in

clinical research?• Consider the future: How AI might be used in years to come?


14:25 Machine learning for medical image analysis• Hear how machine learning techniques are being applied to the automatic interpretation of medical

imaging• What are the benefits of using these techniques within the radiology setting?• Where else could these algorithms be applied?

Antonio Criminisi, Principal Researcher, Microsoft Research




14:45 Novel feature selection strategies for enhanced predictive modelling and deeplearning in the biosciences• Gain an understanding of how WuXi NextCODE’s robust AI method is helping advance personalised

medicine• How do their various advanced deepCODE AI tools expand the understanding of the underlying

molecular determinants of human cancer?• What are these support systems and research tools enabling for the research communities working in

this space?

Tom Chittenden, Vice President, Statistical Sciences and Founding Director, AdvancedArtificial Intelligence Research Laboratory, WuXi NextCODE
















£1,745Save £200

£1,845Save £100

£1,945










Transforming Big Data into Smart Data
















TRANSFORMING BIG DATA INTO SMART DATA

RARE DISEASES

14:20 Collecting and storing standardised clinical data within rare diseases• How has working within rare diseases forced a more progressive approach to biodata?• What role has automation played throughout the rare disease analysis pipeline?• What are some of the challenges integrating genomic and clinical data from a standardisation

perspective?

Richard Scott, Clinical Lead for 100,000 Genomes Project Rare Disease, GenomicsEngland

14:40 The role of data in drug repurposing for rare diseases• Delve into the role data has played in the ability to repurpose existing drugs for treating rare diseases• How does machine learning along with biodata analysis enable these drugs to be matched with

diseases?• What’s next for this approach?

Tim Guilliams, CEO, Healx

15:00 Case Study: GenIDA• Hear an overview of the Genetically determined Intellectual Disabilities and Autism Spectrum Disorders

database• How has this database overcome the challenge of collecting clinical data from patients with rare

diseases?• What effect is this database having on an international scale and how can it be applied to other forms

of rare diseases?

Jean Louis Mandel, Professor of Human Genetics, Collège de France

15:20 The role of biodata from rare disease discovery to clinical application• How is the growth in precision medicine and biodata helping to accelerate progress in the development

of treatment for rare diseases?• Where are there still pitfalls in rare disease data that can be addressed?• What is the biggest opportunity moving forward for biodata and rare diseases?

Vishal Sahni, Director, Pipeline Strategy and R&D Partnerships, Rare Diseases Unit,GSK






OTHER THERAPEUTIC AREAS


Mark Ibberson, Bioinformatics Scientist, Vital-IT, Swiss Institute of Bioinformatics

16:25 Renal virtual clinics and online monitoring of kidney disease• Updates on collecting data from patients doing dialysis at home and from a virtual clinic• Lessons learnt from this format of data collection that can be applied across other therapeutic areas• Explore clinical benefits being seen as a result of this data

Patrick Harnett, Consultant physician and nephrologist, Southend UniversityHospital NHS Foundation Trust

16:45 New Releases from the American Heart Association’s Institute for PrecisionCardiovascular Medicine• Gain an understanding of the AHA’s initiative, My Research Legacy• Learn about the AHA Precision Medicine Platform and how this hub of data is impacting on

developments in cardiovascular medicine• What new grants and research projects are coming out of AHA’s Institute for Precision Cardiovascular

Medicine?

Jennifer Hall, Chief, Institute for Precision Cardiovascular Medicine, American HeartAssociation

17:05 Case Study: Moorfields Eye Hospital – DeepMind Health Collaboration• Hear an overview of the collaboration where they are training an algorithm to diagnose retinal diseases• What have been some of the challenges to overcome within this particular project?• What are the biggest opportunities on offer by using AI technology within ophthalmology?

Pearse Keane, NIHR Clinician Scientist and Honorary Consultant Ophthalmologist,Moorfields Eye Hospital NHS Foundation Trust

17:25 Case Study: Diabetes

Mark Ibberson, Bioinformatics Scientist, Vital-IT, Swiss Institute of Bioinformatics




CANCER

11:05 Case Study: Translational bioinformatics in oncology• What translational bioinformatics is in an academic and multidisciplinary environment within the field

of oncology• What are some of the strategies, issues and bottlenecks encountered during recent studies?• Review a platform developed for NGS automated data management

Emanuele De Rinaldis, Honorary Senior Lecturer & Head of TranslationalBioinformatics, NIHR Biomedical Research Centre, Kings College of London

11:25 Biodata and research into brain tumours• Is big data an opportunity or challenge for research into brain tumours?• How can those affected by brain tumours lead us on use of their data?• How can biobanking help advance developments within this space?

David Jenkinson, Chief Scientific Officer, The Brain Tumour Charity

11:45 Integrating knowledge biocuration with computational biology in cancer• Hear an overview of the biocuration-based activities being undertaken by the SIB Swiss Institute of

Bioinformatics in the field of cancer• Best practices for transforming big data into smart data within this research and development field• Gain insights into biota analytics for drug repurposing in immunotherapy

Ioannis Xenarios, Director, Swiss-Prot/Vital-IT Group, Swiss Institute ofBioinformatics



BIODATA FOR HEALTH SYSTEMS

13:45 Lessons learnt from changing clinical pathways to embed genomic testing• How do we work with hospitals to embed genomic testing in clinical pathways where appropriate?• What tools are needed by healthcare to adopt?• What is the clinical impact of this change, including impact on cost and value?

Stuart Bayliss, Business Support Manager, Central Manchester University HospitalsN.H.S. Foundation Trust




14:05 Case Study: Connected Health Cities and the ‘Learning Health System’• Explore how this project unites health data and technology to improve health services in Northern

England• Review how applications of advanced data analytics have provided more efficient processes and

improved public health to patients• What are some of the lessons learnt that can be applied elsewhere in the UK and the rest of the world?

Tjeerd Van Staa, Professor in Health e-Research, The University of Manchester

14:25 Using AI to diagnose rare diseases• Hear an overview of how AI is helping review patient records and medical literature to generate a series

of ranked diagnoses• What have been some of the lessons learnt and challenges overcome?• Does working with rare diseases alter data protocols and practices at all?

Andreas Jerrentrup, Deputy Director, Undiagnosed and Rare Diseases Centre,University Hospital of Giessen and Marburg
















£1,745Save £200

£1,845Save £100

£1,945










Data Discovery & Generation/InnovationShowcase/Population & Public Health
















DATA SOURCES

INNOVATIONS IN DATA SOURCES AND ACQUISITIONTECHNOLOGIES

14:20 Standardising data capture• How does the biodata community need to come together to standardise the language used in data

capture?• How does this differ between genomic and clinical data?• What role does incentivising data generators play in the standardisation of the data captured?


14:40 How micro-physiological systems (MPS) are enabling innovations in datageneration• Gain an overview of where MPS or ‘organ on chips’ technology currently is and the role it is playing

within the pharma industry• What are some of the benefits of this technology on data generation?• What can we expect from this technology in the future with regards to biosensors and real time

monitoring?

Lorna Ewart, Head of IMED MPS Centre of Excellence, AstraZeneca

15:00 Biobanks as a data resource• Hear an overview of the current status of biobanking and how they consume data• What are some of the challenges around getting clinical sample data, a different kind of big data?• What role do biobanks play with regards to data linkage and anonymization?

Phil Quinlan, Director, UKCRC Tissue Directory and Coordination Centre

15:20 Cognitive Search & Analytics: Building a next-generation search platform forbiodata• Overcoming the challenges of working with large, diverse datasets, of both structured and

unstructured, from internal and external sources within pharmaceutical R&D• How is this platform enabling companies to accelerate research and shorten Drug Time-to-Market?• Examine how this approach is driving innovation within research whilst maintaining information

governance and security

Hans-Josef Jeanrond, , Sinequa





INNOVATION SHOWCASE

INNOVATION SHOWCASE

16:25 Innovation ShowcaseConcise 10 minute presentations reserved for start-ups and SMEs within the biodata industry toshowcase their latest products and services.

Contact Alistair Wilmot ([email protected]/ +44(0)20 7092 1174) for more information on howyou can join the Innovation Showcase


















POPULATION & PUBLIC HEALTH

BIODATA AND EPIDEMIOLOGY

11:05 Understanding disease outcomes with biodata• Gain an understanding of how biodata is assisting epidemiology studies within drug development and

equally drug failures• What are some of the challenges around availability of data when looking at real world evidence and

disease outcomes?• How have population centric phenotypic data helped within this approach?

Athula Herath, Global Head of Real world Evidence Disease Epidemiology, Novartis

11:25 Link between population-level epidemiology and genetic data• What can you learn from linking population-level EHRs and genetic data?• How can you use other technologies to better understand a disease, such as wearables and other data

systems, to track and manage people over time?• How do you overcome the challenge of finding the longitudinal phenotypic data required for these

studies?

Andrew Roddam, Vice President & Global Head Epidemiology, GSK

11:45 Microbial bioinformatics and epidemiology• Gain an understanding of advancements in software development and data analysis within the field of

microbial bioinformatics• How is biodata specifically working towards combatting anti-microbial resistance?• What new methods and technologies are being developed within the microbial bioinformatics space?

Owen Lancaster, Bioinformatics and Epidemiology Analyst, Public Health England





POPULATION & PUBLIC HEALTH

BIODATA FOR POPULATION AND PUBLIC HEALTH APPLICATIONS

13:45 The role of bioinformatics in fighting infectious diseases• Hear how bioinformatics tools are being used for pathogen identification and typing, as well as

pathogenicity and virulence within infectious diseases• How is this research helping to identify and combat antimicrobial resistance?• Gain an understanding of applications for bioinformatics within infectious diseases: drug resistance

testing, pathogen-host interaction, infection and treatment outcomes

Amr Saeb, Head, Genetics and Biotechnology Department, Strategic Center forDiabetes Research, King Saud University, Kingdom of Saudi Arabia

14:05 "Predictive Prevention"• Learn about how the Data for Good Foundation is collecting patient data for research on top of

personal data storage• What is the dynamic around data ownership and governance?• How are the foundation interacting with both health and behaviour data?

Claus Nielsen, Public Affairs, Personal Connected Health Alliance

14:25 Using biodata to understand the causes of disease as a basis of diseaseprevention• Explore how population-based studies are enabling strategies for prevention• Investigate methodologies that can be applied to biobanks and population-based cohorts when

studying disease prevention• Best practices in overcoming challenges with global coverage and international collaborations

Zdenko Herceg, Head, Section of Mechanisms of Carcinogenesis, InternationalAgency for Research on Cancer (IARC/WHO)
















£1,745Save £200

£1,845Save £100

£1,945










2 - 3 november 2017 cambridge - embl-ebi · biodata eu 2017 day 1 08:55 chair’s opening remarks...

Documents